Business Description
Realcan Pharmaceutical Group Co Ltd
NAICS : 325412
ISIN : CNE1000013X5
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.67 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.28 | |||||
Debt-to-EBITDA | 69.49 | |||||
Interest Coverage | 0.28 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.89 | |||||
Beneish M-Score | -2.52 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -34.2 | |||||
3-Year EBITDA Growth Rate | -40.7 | |||||
3-Year FCF Growth Rate | 2.7 | |||||
3-Year Book Growth Rate | -10 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 19.17 | |||||
9-Day RSI | 32.07 | |||||
14-Day RSI | 40.13 | |||||
6-1 Month Momentum % | 45.37 | |||||
12-1 Month Momentum % | -3.38 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.14 | |||||
Quick Ratio | 1.05 | |||||
Cash Ratio | 0.46 | |||||
Days Inventory | 47.79 | |||||
Days Sales Outstanding | 178.36 | |||||
Days Payable | 222.97 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.65 | |||||
Dividend Payout Ratio | 0.48 | |||||
Forward Dividend Yield % | 0.65 | |||||
5-Year Yield-on-Cost % | 0.68 | |||||
Shareholder Yield % | -38.1 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 10.01 | |||||
Operating Margin % | 0.79 | |||||
Net Margin % | 0.5 | |||||
FCF Margin % | -6.82 | |||||
ROE % | 0.73 | |||||
ROA % | 0.24 | |||||
ROIC % | -0.27 | |||||
ROC (Joel Greenblatt) % | 3.39 | |||||
ROCE % | 1.68 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 111.11 | |||||
Shiller PE Ratio | 60 | |||||
PS Ratio | 0.56 | |||||
PB Ratio | 0.82 | |||||
Price-to-Tangible-Book | 0.93 | |||||
EV-to-EBIT | 68.66 | |||||
EV-to-EBITDA | 68.66 | |||||
EV-to-Revenue | 0.87 | |||||
EV-to-FCF | -12.71 | |||||
Price-to-Projected-FCF | 0.5 | |||||
Price-to-Median-PS-Value | 1.15 | |||||
Price-to-Net-Current-Asset-Value | 6.98 | |||||
Earnings Yield (Greenblatt) % | 1.46 | |||||
FCF Yield % | -11.83 | |||||
Forward Rate of Return (Yacktman) % | -27.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Realcan Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 7,985.499 | ||
EPS (TTM) (Â¥) | 0.027 | ||
Beta | 0.6 | ||
Volatility % | 41.53 | ||
14-Day RSI | 40.13 | ||
14-Day ATR (Â¥) | 0.130842 | ||
20-Day SMA (Â¥) | 3.2825 | ||
12-1 Month Momentum % | -3.38 | ||
52-Week Range (Â¥) | 2.05 - 3.67 | ||
Shares Outstanding (Mil) | 1,504.71 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Realcan Pharmaceutical Group Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Realcan Pharmaceutical Group Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Realcan Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Realcan Pharmaceutical Group Co Ltd(SZSE:002589)'s stock price today?
When is next earnings date of Realcan Pharmaceutical Group Co Ltd(SZSE:002589)?
Does Realcan Pharmaceutical Group Co Ltd(SZSE:002589) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |